Abdera Therapeutics

Wishing a happy #Thanksgiving day to all our colleagues, family, and friends in Canada! The Abdera team sends warm greetings as we all take time to enjoy the beauty of autumn and the spirit of togetherness this holiday brings.

Cancer affects countless lives each year, and at Abdera, we are committed to driving change and helping build a future free of it. We're honored to have been sponsors of the American Cancer Society's 13th Annual San Francisco Discovery Gala. We were inspired by the evening's shared hope and dedication to supporting #ACS in their mission to fight #cancer. 

Our team had a great time attending the Fierce Biotech #Fierce15 Award Ceremony in Boston this week, celebrating and connecting with the top innovators in #biotech. We are grateful for our team’s dedication, which has allowed us to continue pushing boundaries and making strides in transforming treatment options. Congratulations to all of this year’s honorees!

Another successful 5K for #TeamAbdera! Some of our SSF team members joined the GO2 for Lung Cancer Foundation’s 5K, seizing the chance to get moving for a cause close to our hearts. “It was a great, energetic, and friendly crowd, full of people supporting those who have been impacted by lung cancer,” shares Carly Loeb, PhD.

Our very own, co-founder and chief operating officer, Lana Janes, Ph.D., recently took the stage to represent Abdera during a panel discussion about the biologic revolution in #radiotherapies at the 2024 World Medical Innovation Forum in Boston. We’re proud to have been part of this important conversation shaping the future of #cancer care. #WMIF2024

We’re proud to share that Executive Director, Biologics, Emma Cummins, has been selected to join the prestigious adMare BioInnovations Academy Executive Institute. This highly selective program admits only 20 participants each year and stands at the forefront of leadership cultivation. It’s designed to foster growth and learning in the industry. We look forward to all that you will achieve, Emma!

This past weekend, some of the Abdera team members had the amazing opportunity to participate in the #TerryFoxRun at Vancouver’s Stanley Park to support cancer research. Inspired by Terry Fox's Marathon of Hope, the annual run continues his legacy of courage and determination, uniting people to support the fight against #cancer. Together, we’re running with hope and purpose, pushing the boundaries of innovation to help patients worldwide.

Abdera Chief Medical Officer, Philippe Bishop MD, will join a virtual panel at the Endpoints News at #ESMO24 to discuss the rising popularity of #radiopharmaceuticals, the latest clinical findings, challenges, and how pharma companies are positioning in this evolving field. Learn more about our precision #radiotherapeutics platform here: https://lnkd.in/gR5GcxDa

We are seeking a highly motivated individual looking for an opportunity as a Clinical Operations Senior Study Management Associate to help support innovative radiopharmaceutical-based #oncology clinical studies. If you are an individual who wants to be part of a dynamic, fast-paced environment, and willing to take on new challenges, Abdera is the place to be! Learn more about #LifeAtAbdera and apply here: https://lnkd.in/g568us_s

We are excited to announce that the FDA has granted Orphan Drug Designation to ABD-147 for the treatment of neuroendocrine carcinoma. ABD-147 is a next-generation precision #radiopharmaceutical therapy designed to deliver Actinium-225 to solid tumors expressing DLL3, a protein found on the surface of neuroendocrine tumors, but rarely expressed on the surface of normal cells or tissues. Learn more about our novel treatment and innovative ROVEr™ platform here: https://lnkd.in/eh7kdqe8